A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence
Launched by ABBVIE · Apr 24, 2024
Trial Information
Current as of May 24, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of BOTOX injections to help reduce the appearance of a prominent masseter muscle, which is the muscle in your jaw used for chewing. Some people feel that having a wider jawline is not aesthetically pleasing, and this study aims to see how safe and effective BOTOX is for adults with this condition. If you are an adult aged between 18 and 65 with a significant prominence in both sides of your jaw, you might be eligible to participate.
During the trial, participants will be divided into two groups: one will receive BOTOX injections, while the other will receive a placebo (a substance with no active treatment). This means there's a chance you could receive the placebo. You will receive injections in both sides of your jaw and may have the option to receive more BOTOX after the initial treatment. Throughout the study, you will attend regular visits to monitor your progress and any side effects. It’s important to note that participation may require more time and visits than standard treatment, as the study aims to thoroughly assess how well the treatment works and how safe it is.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Participant meets the following criteria:
- • Bilateral Grade 4 or Grade 5 Masseter Muscle Prominence (MMP) (identical grades for left and right sides of the face), as determined at by the investigator using the Masseter Muscle Prominence Scale (MMPS).
- • Bilateral Grade 4 or Grade 5 MMP (identical grades for left and right sides of the face), as determined by the participant using the Masseter Muscle Prominence Scale - Participant (MMPS-P).
- • Investigator and participant scoring of MMPS and MMPS-P must be the same.
- • Body mass index (BMI) ≤ 30 kg/m\^2 using the calculation: BMI = weight (kg)/height (m)\^2.
- Exclusion Criteria:
- • Excess lower facial fat, jowling, loose or lax skin in lower face, or parotid gland prominence that could interfere with MMPS or MMPS-P grading.
- • Asymmetry of left and right sides of the face that could prevent identical MMPS or MMPS-P grading on both sides of the face.
- • History of or current temporomandibular disorder (TMJD), or presence of signs/symptoms of possible TMJD.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Orleans, Louisiana, United States
Clarkston, Michigan, United States
Santa Monica, California, United States
Westport, Connecticut, United States
Metairie, Louisiana, United States
Wilmington, North Carolina, United States
Dublin, Ohio, United States
Nashville, Tennessee, United States
Pflugerville, Texas, United States
Bradenton, Florida, United States
San Diego, California, United States
Arlington, Virginia, United States
Los Angeles, California, United States
Dallas, Texas, United States
Pflugerville, Texas, United States
Birmingham, Alabama, United States
Metairie, Louisiana, United States
Hackensack, New Jersey, United States
Latham, New York, United States
Bellaire, Texas, United States
Phoenix, Arizona, United States
Miami, Florida, United States
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported